Adequacy of the treatment of hypertensive patients with metabolic syndrome;Adecuación del tratamiento de los pacientes hipertensos con síndrome metabólico

Medicina Clinica

Volumn 128, Issue 17, 2007, Pages 647-651

  Barrios, Vivencio ^a   Escobar, Carlos ^a   Calderón, Alberto ^b   Llisterri, José Luis ^c   Alegría, Eduardo ^d   Muñiz, Javier ^e   Matalí, Arantxa ^f  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Centro de Salud Rosa de Luxemburgo   (Spain)

^c Centro de Salud Nazaret   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e HOSPITAL JUAN CANALEJO   (Spain)

^f Almirall Prodesfarma ^*  (Spain)

Author keywords

Control; Hypertension; Lipids; Metabolic syndrome; Primary health care; Spain

Indexed keywords

ANTIHYPERTENSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; TREATMENT OUTCOME;

EID: 34347251925     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13102050     Document Type: Article

References (28)

1. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ. 2006;332:878-82.
2. Haffner SM. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Am J Med. 2006; 119:S3-S9.
3. Reaven GM. Role of insulin resistance in human disease. Banting lecture 1988. Diabetes. 1988; 37:1595-607.
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-21.
5. Alberti KGMM, Zimmet PZ, Shaw JE. The metabolic syndrome - a new world-wide definition from the International Diabetes Federation consensus. Lancet. 2005;366:1059-62.
6. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-7.
7. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415-28.
8. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004; 33:351-76.
9. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol. 2004;43:1817-22.
10. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-9.
11. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens. 2004;22:1991-8.
12. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-53.
13. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551-6.
14. De la Sierra A, Romero R, Bonet J, Pérez M, López JS, Ravella R, et al. Prevalencia y características del síndrome metabólico en la población hipertensa espahola. Med Clin (Barc). 2006; 126:406-9.
15. Coca A, Dalfo A, Esmatjes E, Llisterri JL, Ordóñez J, Gomis R, et al. Tratamiento y control del riesgo cardiovascular en atención primaria en España. Estudio PREVENCAT. Med Clin (Barc). 2006;1265:201-5.
16. González JR, Alegría E, Lozano JV, Llisterri JL, García JM, González I. Impacto de la hipertensión en las cardiopatías en España. Estudio CARDIOTENS 1999. Rev Esp Cardiol. 2001;54: 139-49.
17. Sever P, Dahlöf B, Poulter N, Wedel H, Beevers G, Caulfield M, et al. For the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.
18. Hansson L, Lithell H, Skoog I, Bara F, Bánki CM, Breteler M, et al. Study on Cognition and Prognosis in the Elderly (SCOPE): baseline characteristics. Blood Press. 2000;9:146-51.
19. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-6.
20. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
21. Lindholma LH, Perssona M, Alaupovicb P, Carlberga B, Svenssonc A, Samuelssond O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21:1563-74.
22. Weber M, Julius S, Kjeldsen SE, Brunner H, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049-51.
23. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Results of the HOPE and micro-HOPE study. Lancet. 2000;355:253-9.
24. Coca A. Evolución del control de la hipertensión arterial en España. Resultados del estudio Controlpres 2001. Hipertension. 2002;19:390-9.
25. Banegas JR. Epidemiología de la hipertensión arterial en España. Situación actual y perspectivas. Hipertensión. 2005;22:353-62.
26. Llisterri JL, Rodríguez GC, Alonso FJ, Lou S, Divison JA, Santos JA, et al. Control de la presión arterial en la población hipertensa española atendida en atención primaria. Estudio PRES-CAP 2002. Med Clin (Barc). 2004;122:165-71.
27. Backlund L, Bring J, Strender L-E. How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients. Primary Health Care Research and Development. 2004;5:145-52.
28. Barrios V, Campuzano R, Peña G, Guzmán G, Ruilope LM. Estratificación del riesgo cardiovascular en hipertensión en atención primaria e impacto sobre el tratamiento antihipertensivo. Estudio DIORISC. Hipertension. 2002;19:114-20.